Skip to main content
    V

    VistaGen Therapeutics Inc (VTGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.18
    +0.00 (+2.11%)

    Market Cap: $8.01M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    53%(21/40)
    Avg Surprise
    -19.36%
    Streak
    1 Q

    Upcoming Estimates

    Reports Feb 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.37
    Range-$0.37 - -$0.36
    2 analysts
    EPS Revisions
    0
    2
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.370.0%
    60d ago-$0.370.0%
    30d ago-$0.36-1.4%
    7d ago-$0.36-1.4%
    Current-$0.37
    Revenue Consensus
    $250.00K
    RangeN/A
    2 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus-$0.37
    RangeN/A
    4 analysts
    Revenue Consensus
    $255.00K
    RangeN/A
    4 analysts

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-2543.00%
    ROE-145.00%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio2.64xQuick Ratio2.64x
    Trading Statistics
    Beta0.47Avg Volume776.84K
    52-Week High$5.1452-Week Low$0.16

    Technical Indicators Dashboard

    As of Nov 16, 2026, the price is 16.9% below its 50-day moving average, and the 50-day average is below the 200-day average. The 14-day RSI is 45.5, in the neutral range between 30 and 70.

    Moving Averages

    SMA 10$0.18
    SMA 20$0.18
    SMA 50$0.22
    SMA 200$0.42
    EMA 10$0.18
    EMA 20$0.19
    EMA 50$0.22
    EMA 200$0.65

    MACD

    Line: -0.01Signal: -0.02Hist: 0.00

    ADX

    ADX: 11.2+DI: 18.1-DI: 19.9

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down76.0
    PSAR$0.19

    Bollinger Bands

    Upper Band$0.20
    Lower Band$0.16
    %B Position2179%(Upper)
    Band Width0.66

    RSI (14-Day)

    Neutral
    45.5

    Momentum Oscillators

    Stoch %K64.5
    Stoch %D67.3
    Williams %R-26.0
    ROC (10d)10.0%
    Momentum0.02
    CCI (20d)21.2
    MFI (14d)53.5

    Volatility Measures

    ATR (14d)$0.02(9.0%)
    StdDev (20d)0.01
    Hist Vol77.2%(High)

    Volume Flow

    VWAP$0.18
    OBV557.4M
    AD Line-363.4M
    CMF (20d)-0.173

    Volume Metrics

    Avg Vol (20d)763.6K
    Vol Ratio1.8x(High)
    VWMA (20d)$0.18

    Pivot Points

    R3$0.19
    R2$0.19
    R1$0.18
    Pivot Point$0.18
    S1$0.18
    S2$0.17
    S3$0.17

    Advanced Oscillators

    TSI-19.92
    Ultimate Osc53.3
    KST-216.97

    Financial Performance

    Related GNG Research

    No research available

    Be the first to write about VTGN

    News

    VTGN Valuation

    GNG's valuation label for VTGN is Undervalued.

    P/B
    0.5x
    All VTGN metrics

    VTGN Profitability: Margins, ROIC and FCF

    VistaGen Therapeutics (VTGN) has a gross margin of 100.0%, an operating margin of -2543.0% and a net margin of 0.0%. It posts a -2555.7% FCF margin.

    Gross margin
    100.0%
    Operating margin
    -2543.0%
    Net margin
    0.0%
    ROE
    -145.0%
    FCF margin
    -2555.7%
    VTGN financial statements

    VistaGen Therapeutics Competitors

    The companies most similar to VistaGen Therapeutics (VTGN) include Biovie, Tempest Therapeutics and Theriva Biologics.

    Sector: Healthcare

    Companies most similar to VistaGen Therapeutics

    VTGN Analyst Ratings

    VistaGen Therapeutics (VTGN) has a Hold consensus from 4 analysts: 0 Buy or Strong Buy, 4 Hold and 0 Sell or Strong Sell.

    Consensus
    Hold
    Analysts
    4
    Strong Buy
    0
    Buy
    0
    Hold
    4
    Sell
    0
    Strong Sell
    0
    VTGN stock forecast

    VTGN Bull Case vs Bear Case

    Bear case

    • VTGN's quarterly revenue changed -46.5% year over year.

    VTGN Earnings: Beat Rate and Next Report

    VistaGen Therapeutics (VTGN) beat the EPS estimate in 5 of the last 8 quarters (62.5%). Its next report is expected on Feb 10, 2027.

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    10.9%
    EPS estimate (fiscal period ending Dec 31, 2026)
    -$0.37
    Estimate revisions (30 days, fiscal period ending Dec 31, 2026)
    0 up, 2 down
    VTGN earnings history

    VTGN Earnings Date

    VTGN reports Feb 10, 2027. The date is estimated.

    VTGN Earnings Call

    The latest VTGN earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    See insider activity

    Updated Nov 13, 2026. Built from end-of-day prices, company filings and consensus analyst estimates. Methodology

    Frequently Asked Questions About VTGN

    When does VTGN report earnings?

    VistaGen Therapeutics Inc (VTGN) is expected to report earnings on Feb 10, 2027.

    Does VTGN pay dividends?

    VistaGen Therapeutics Inc (VTGN) does not currently pay a regular dividend.

    What is VTGN's market cap?

    VistaGen Therapeutics Inc (VTGN) has a market capitalization of $8.01M with a current stock price of $0.18.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.